This document summarizes recent advancements in healthcare devices and pharmaceutical products by Abbott Laboratories. It discusses Abbott's nutrition care products including oral rehydration drinks, diabetes care technologies like continuous glucose monitors, diagnostics tests like BinaxNOW tests for COVID-19, heart health devices, and neuromodulation systems for pain management like Proclaim DRG neurostimulation. Abbott was established in 1910 and specializes in products for cardiovascular health, diagnostics, diabetes, and pain treatment, impacting over 100,000 people globally.

1. RECENT ADVANCEMENT IN HEALTHCARE DEVICES AND
PHARMACEUTICAL PRODUCTS
 FT

2. NUTRITION CARE
DIABETES CARE
DIAGNOSTICS TESTING
HEALTHY HEART
PAIN AND MOVEMENT CARE
SWARNA PRIYA B
DOCTOR OF PHARMACY INTERN

3. INTRODUCTION
 Established in 1910
 Abbott Laboratories is an American multinational medical devices and health care company with headquarters in
Abbott Park, Illinois, United States.
 It specializes in cardiovascular, diagnostics, diabetes and neuromodulation products.
 Today around 109,000 people in 160 countries including India have been lasting impact in healthcare so far.

4. FOUNDER

5. IMPORTANT PEOPLE

6. OVERVIEW

7. NUTRITION CARE

8. NUTRITION CARE
 Importance of electrolytes in athletes –
rehydration and muscle support
 25% of sugar
 The 5 key electrolytes are
• Sodium to avoid muscle cramping
• Chloride for fluid balance
• Potassium for muscle and nerve function
• Magnesium to help provide oxygen to muscles
• Phosphate for muscle repair

9. COMPARE AND CONTRAST WITH OTHER ORAL REHYDRATIONS

10. COMPARE AND CONTRAST WITH SUGAR LEVELS

11. OTHER NUTRITION CARE BY ABBOTT

12. DIABETES CARE

13. DIABETES CARE
 CGMs which can show the daily highs and lows in a bar graph
• It increases the Time In Range (TIR) - TIR captures time a person spends in their target glucose range, often
shown as a bar graph.
• That range is 70 (hypoglycemia) to 180 mg/dL (hyperglycemia) for most people.
• The target window to be in range is about 17 hours each day, or 70 percent.
 Time in Range is a critical metric for diabetes management because it gives that immediate visibility into glucose
levels
 The more time you spend in range, the less likely you are to develop certain diabetes complications – ADA

14. FREESTYLE LIBRE SYSTEM – SENSOR BASED CGM
 Freestyle Libre Pro and Freestyle Libre use subcutaneous, wired enzyme glucose
sensing technology to detect glucose levels in interstitial fluid.
 They automatically measure glucose every minute, and readings are stored in 15-
minute intervals. The Libre Reader is held near the sensor when a glucose reading is
needed. The reader device will then display the past 8 hours of glucose information,
including current glucose, a trend graph, and a trend arrow. The arrow indicates the
direction and velocity of the patient’s current glucose level.
 Limitations - Not approved in children <18 years of age or for patients who are
pregnant, on dialysis, or critically ill. Patients who are dehydrated or have high levels
of vitamin C or salicylic acid may not get accurate readings with the system.
 The sensor is small and discreet, measuring approximately the size of a quarter. Thus,
patients can wear it for 10–14 days with minimal disturbance of their activities of
daily living.

15. PRODUCT

16. POTENTIAL DISADVANTAGES
 The FDA has identified inaccuracies of the system at lower glucose levels, as seen in the clinical trials of the
system. Although CGM devices in general tend to lose accuracy at lower blood glucose numbers, the Freestyle
Libre is less accurate than previously approved CGM systems.
 Freestyle Libre does not have any alert functions for high or low glucose levels. Other CGM systems provide
programmable limits that alert patients if they are approaching hypoglycemia or hyperglycemia. This feature
serves as a safety net for many patients but is not available with the Freestyle Libre.
 Reference: Blum A. (2018). Freestyle Libre Glucose Monitoring System. Clinical diabetes : a publication of the
American Diabetes Association, 36(2), 203–204. https://doi.org/10.2337/cd17-0130

17. PHASES OF CLINICAL TRIAL

18. COSTS – IS IT AFFORDABLE?

19. DIAGNOSTICS CARE

20. DIAGNOSTICS CARE
 BinaxNow is the most widely used and studied rapid antigen test in the U.S. It provides results within 15
minutes and is authorized in three different ways. It is now available for;
• Influenza types A and B.
• RSV, a common respiratory virus that typically causes mild, common-cold-type symptoms but can be
severe for both young infants and older adults.
• And, of course, COVID-19.
 Can have confidence that our tests are designed to detect variants such as Delta, Mu, R.1 and more.

21. BINAXNOW
The BinaxNOW™ COVID-19 Antigen Self Test is a lateral flow immunoassay intended for the qualitative detection of
nucleocapsid protein antigen from SARS-CoV-2.
Cost: 1,400 INR.

22. CARDIAC CARE

23. HEART FAILURE

24. SLOW OR IRREGULAR HEARTBEAT

25. MITRAL REGURGITATION

26. STROKE

27. DEVICE

28. CHRONIC PAIN MANAGEMENT

29. DRG: LIFE-CHANGING TECHNOLOGY FOR CHRONIC PAIN

30. PROCLAIM DRG NEUROSTIMULATION SYSTEM
 Researchers turned their attention to the dorsal root ganglion (DRG), a bundle of nerves located on the
outside of the spinal cord.
 The DRG was once thought to have no connection to pain, but researchers now know that this nerve
bundle plays a key role in nerve pain for CRPS I and II patients. According to a 2017 study published
in Pain, stimulating the DRG helps relieve pain more effectively than spinal cord stimulation.
 This DRG stimulation therapy involves surgically placing a stimulator that targets the dorsal root
ganglion to relieve pain of the lower limbs due to CRPS (Complex Regional Pain Syndrome). Individuals
have a hand-held iPod controller that changes the stimulation settings within prescribed limits.

31. ADVANTAGES
• 74.2 percent of people experienced meaningful pain relief with DRG stimulation, compared to 53
percent who received traditional spinal cord stimulation.
• One-third had more than 80 percent pain relief and no tingling sensation, which is a common side effect
with traditional spinal cord stimulation.
• DRG stimulation led to a better quality of life compared to traditional spinal cord stimulation.

32. SYSTEM

33. NOTE
 WARNING/PRECAUTIONS:
Diathermy therapy, implanted cardiac systems or other active implantable devices, magnetic resonance imaging
(MRI), computed tomography (CT), electrosurgery devices, ultrasonic scanning equipment, therapeutic radiation,
explosive or flammable gases, theft detectors and metal screening devices, lead movement, operation of machinery
and equipment, pediatric use, pregnancy, and case damage.
 ADVERSE EFFECT:
Painful stimulation, surgical risks (e.g., paralysis). Implant Manual must be reviewed for detailed disclosure. Refer to
the User's Manual for detailed indications, contraindications, warnings, precautions and potential adverse events.
 COST:
Ranges from $7,000-$10,000 depending on the practice.

34. SUPPORTING ALTERNATIVES

35. THANK YOU FOR YOUR PATIENT LISTENING

36. ANY QUESTIONS OR DOUBTS TO BE ANSWERED?

37. NOW THE PANEL IS OPEN FOR DISCUSSION